These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1179 related items for PubMed ID: 11280751

  • 1. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM.
    Cancer Res; 2005 Dec 15; 65(24):11752-61. PubMed ID: 16357188
    [Abstract] [Full Text] [Related]

  • 3. Angiostatin enhances B7.1-mediated cancer immunotherapy independently of effects on vascular endothelial growth factor expression.
    Sun X, Kanwar JR, Leung E, Lehnert K, Wang D, Krissansen GW.
    Cancer Gene Ther; 2001 Oct 15; 8(10):719-27. PubMed ID: 11687895
    [Abstract] [Full Text] [Related]

  • 4. Requirements for ICAM-1 immunogene therapy of lymphoma.
    Kanwar JR, Berg RW, Yang Y, Kanwar RK, Ching LM, Sun X, Krissansen GW.
    Cancer Gene Ther; 2003 Jun 15; 10(6):468-76. PubMed ID: 12768192
    [Abstract] [Full Text] [Related]

  • 5. Induction of systemic antitumor immunity by gene transfer of mammalian heat shock protein 70.1 into tumors in situ.
    Rafiee M, Kanwar JR, Berg RW, Lehnert K, Lisowska K, Krissansen GW.
    Cancer Gene Ther; 2001 Dec 15; 8(12):974-81. PubMed ID: 11781660
    [Abstract] [Full Text] [Related]

  • 6. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J, Chen Y, Moyana T.
    Cancer Gene Ther; 2000 Jul 15; 7(7):1023-33. PubMed ID: 10917205
    [Abstract] [Full Text] [Related]

  • 7. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 8. Mouse B7-H3 induces antitumor immunity.
    Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW.
    Gene Ther; 2003 Sep 01; 10(20):1728-34. PubMed ID: 12939639
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y, Saxena A, Zheng C, Carlsen S, Xiang J.
    J Gene Med; 2004 Aug 01; 6(8):857-68. PubMed ID: 15293344
    [Abstract] [Full Text] [Related]

  • 13. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Kuzushita N, Ito A, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Hepatology; 1999 Aug 01; 30(2):422-9. PubMed ID: 10421650
    [Abstract] [Full Text] [Related]

  • 14. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.
    Cancer Res; 1995 Nov 01; 55(21):4980-7. PubMed ID: 7585539
    [Abstract] [Full Text] [Related]

  • 15. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A, Hu P, Khawli LA, Epstein AL.
    Clin Cancer Res; 2005 Dec 01; 11(23):8492-502. PubMed ID: 16322313
    [Abstract] [Full Text] [Related]

  • 18. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P, De Meyer M, Leroy P, Rousseau C, Acres B.
    Cancer Gene Ther; 2001 May 01; 8(5):321-32. PubMed ID: 11477452
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.